1492MO Immune and vascular biomarkers associated with efficacy and mechanism of actions of the combination of lenvatinib (L) and eribulin (E) in leiomyosarcoma (LMS) and liposarcoma (LPS)

T.W-W Chen,C-L Hsu,J-C Lee,C-C Yen,R-L Hong,S-C Chen,C-W Yu,M-L Chen,M-C Hsu,T-F Kung,A-L Cheng

doi:10.1016/j.annonc.2022.07.1595

1492MO Immune and vascular biomarkers associated with efficacy and mechanism of actions of the combination of lenvatinib (L) and eribulin (E) in leiomyosarcoma (LMS) and liposarcoma (LPS)

T.W-W Chen, C-L Hsu + Show 9 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1595

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: National Taiwan University Hospital, Taipei Veterans General Hospital

#Liposarcoma #Immune-related Biomarkers + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The interactions with immune system and influence on the tumor microenvironment (TME) of L + E remain elusive. The LEADER study (NCT03526679) investigated the efficacy of L + E in advanced LMS and LPS and immune-related biomarkers were examined.

Full Text